Compounds > catechin

catechin and afimoxifene

catechin has been researched along with afimoxifene in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Larsen, L; Rosengren, RJ; Stuart, EC1
Choi, JS; Shin, SC1
Collado-González, Mdel M; Fernández-Pérez, MP; Gamkrelidze, M; Hammouda, MB; Montenegro, MF; Rodríguez-López, JN; Tolordava, L1

Other Studies

3 other study(ies) available for catechin and afimoxifene

ArticleYear
Potential mechanisms for the synergistic cytotoxicity elicited by 4-hydroxytamoxifen and epigallocatechin gallate in MDA-MB-231 cells.
    International journal of oncology, 2007, Volume: 30, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Catechin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Tamoxifen

2007
Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
    Anti-cancer drugs, 2009, Volume: 20, Issue:7

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Hormonal; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Catechin; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Injections, Intravenous; Intestinal Mucosa; Liver; Male; Rats; Rats, Sprague-Dawley; Tamoxifen

2009
Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells.
    BMC cancer, 2014, Jul-26, Volume: 14

    Topics: Apoptosis; Breast Neoplasms; Catechin; Cell Line, Tumor; Cell Proliferation; Dipyridamole; Drug Resistance, Neoplasm; Drug Synergism; E2F1 Transcription Factor; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Tamoxifen

2014